Baseline characteristics and 30-day clinical outcomes
| Demographics . | Controls (N = 49) . | Patients with COVID-19 (N = 81) . |
|---|---|---|
| Median age, y (range) | 40.0 (20-77) | 64.0 (24-85) |
| Sex, n (%) male | 17 (34.7) | 49 (60.0) |
| Median BMI, kg/m2 (IQR) | 25.9 (19.2-31.5) | 33.2 (21.4-50.9) |
| Median laboratory values (IQR) | ||
| White blood cell count (×109/L) | 5.3 (2.4-6.0) | 10.1 (3.4-27.7) |
| Neutrophil count (×109/L) | 3.2 (1.7-3.3) | 7.6 (0.6-25.4) |
| Lymphocyte count (×109/L) | 1.6 (0.6-2.8) | 0.8 (0.1-3.1) |
| Monocyte count (×109/L) | 0.4 (0.1-0.9) | 0.5 (0.1-1.3) |
| Platelet count (×109/L) | 252 (158-442) | 242 (85-712) |
| Hemoglobin (g/dL) | 14.8 (13.8-16.1) | 12.4 (6.7-16.5) |
| Hematocrit (%) | 43.2 (40.3-46.5) | 38.0 (21.0-48.0) |
| D-dimer (μg/mL FEU) | ND∗ | 1.8 (0.2->35) |
| Fibrinogen (mg/dL) | ND∗ | 542 (174-1000) |
| Clinical outcomes | ||
| 30-Day mortality, n (%) | 0 | 19 (23.4) |
| ICU admission, n (%) | 0 | 59 (72.8) |
| Intubation, n (%) | 0 | 31 (38.3) |
| Acute kidney injury, n (%) | 0 | 18 (22.2) |
| Arterial thrombosis, n (%) | 0 | 5 (6.2) |
| Venous thrombosis, n (%) | 0 | 5 (6.2) |
| Major or minor bleeding, n (%) | 0 | 15 (18.5) |
| Median length of hospitalization, d (IQR) | 0 | 9.5 (1-24) |
| Demographics . | Controls (N = 49) . | Patients with COVID-19 (N = 81) . |
|---|---|---|
| Median age, y (range) | 40.0 (20-77) | 64.0 (24-85) |
| Sex, n (%) male | 17 (34.7) | 49 (60.0) |
| Median BMI, kg/m2 (IQR) | 25.9 (19.2-31.5) | 33.2 (21.4-50.9) |
| Median laboratory values (IQR) | ||
| White blood cell count (×109/L) | 5.3 (2.4-6.0) | 10.1 (3.4-27.7) |
| Neutrophil count (×109/L) | 3.2 (1.7-3.3) | 7.6 (0.6-25.4) |
| Lymphocyte count (×109/L) | 1.6 (0.6-2.8) | 0.8 (0.1-3.1) |
| Monocyte count (×109/L) | 0.4 (0.1-0.9) | 0.5 (0.1-1.3) |
| Platelet count (×109/L) | 252 (158-442) | 242 (85-712) |
| Hemoglobin (g/dL) | 14.8 (13.8-16.1) | 12.4 (6.7-16.5) |
| Hematocrit (%) | 43.2 (40.3-46.5) | 38.0 (21.0-48.0) |
| D-dimer (μg/mL FEU) | ND∗ | 1.8 (0.2->35) |
| Fibrinogen (mg/dL) | ND∗ | 542 (174-1000) |
| Clinical outcomes | ||
| 30-Day mortality, n (%) | 0 | 19 (23.4) |
| ICU admission, n (%) | 0 | 59 (72.8) |
| Intubation, n (%) | 0 | 31 (38.3) |
| Acute kidney injury, n (%) | 0 | 18 (22.2) |
| Arterial thrombosis, n (%) | 0 | 5 (6.2) |
| Venous thrombosis, n (%) | 0 | 5 (6.2) |
| Major or minor bleeding, n (%) | 0 | 15 (18.5) |
| Median length of hospitalization, d (IQR) | 0 | 9.5 (1-24) |
BMI, body mass index; FEU, fibrinogen equivalent units; ICU, intensive care unit; IQR, interquartile range.
Not determined.